G.K.S. is on a Data and Safety Monitoring Board for a GlaxoSmithKline - funded
RSV vaccine study in pregnant women.
Not exact matches
The
study showed that the
vaccine being tested elicited more
RSV antibodies in young children than a previous
RSV vaccine candidate.
«If this research is borne out in future
studies, we could be less than a decade away from a safe and effective live - attenuated
vaccine for
RSV.»
«An
RSV vaccine with this M2 - 2 deletion could tip the balance toward a better immune response, which is what we predicted based on earlier laboratory
studies,» says
study leader Ruth A. Karron, MD, director of the Center for Immunization Research and a professor in the Department of International Health at the Bloomberg School.
Kang's primary research focuses on designing and developing effective
vaccines against viral diseases such as influenza virus and
RSV, but he partnered with a university and research institutes in South Korea that wanted international collaborative projects to
study if ginseng can be used to improve health and protect against disease because of the potential benefit in fighting these viruses.
«Investigational
vaccine protects cattle from respiratory syncytial virus:
Study provides model for developing an effective human
RSV vaccine.»
The version of
RSV that naturally infects cattle is closely related to human
RSV, so the results suggest that a similar human
RSV vaccine construct may provide protection in humans, according to the
study authors.
Subsequent
studies in animal models that are thought to mimic the human experience indicate
RSV inactivated
vaccine induces an increased CD4 + T lymphocyte response, primarily of Th2 cells and the occurrence of immune complex depositions in lung tissues [32], [42], [43].
She has received research funding for
studies of GBS
vaccine in pregnant women produced by Novartis, for
RSV vaccine in pregnant women produced by Novavax, and for
RSV mAb in late preterm infants produced by Regeneron.
In this regard, animal model
studies with FIPV in cats and
RSV in mice have indicated that viral surface proteins may be the sensitizing protein of inactivated
vaccines for immunopathology with infection [32], [45].